Clinical trials: Phyllodes Tumor, active
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Radiotherapy, Adjuvant, Phyllodes Breast Tumor
Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial.
- Conditions
- Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis, Molecular Typing
- Trial name
- NCT07657169
- Testing
- Postoperative Radiotherapy (PORT)
- Where
- 4 sites in China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Phyllodes Tumor of the Breast
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
Malignant phyllodes tumor of the breast is a rare fibroepithelial tumor. Patients with metastatic or unresectable disease have limited systemic treatment options, and there remains a need for biomarkers that can dynamically…
- Trial name
- NCT07903181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phyllodes Breast Tumor, Artificial Intelligence
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border…
- Conditions
- Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
- Trial name
- NCT06286267
- Testing
- imaging
- Where
- 4 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University